13:00 | 22/04/2021 Companies
(VEN) - Davipharm, one of the leading domestic manufacturers of high-quality generic drugs, a member of Adamed Group, announced the certification of Vietnam’s first High Potency (HP) Drugs Zone for the production of cytotoxic/cytostatic oral solids. These are oncological drugs in hard shell capsules, tablets, and coated tablets.
In November 2017, Adamed Pharma, a Polish pharmaceutical and biotechnology company, acquired the controlling stake in Davipharm, one of the fastest-growing pharmaceutical companies in Vietnam. This is the largest-ever direct private Polish investment in Vietnam.
With over 10 million US dollars invested by Adamed by the end of 2020, Davipharm’s production plant in Binh Duong, Vietnam’s first HP Zone for the production of oncological drugs in solid forms, is an important milestone in terms of investing in high-quality. This will be followed by EU-GMP certification later this year as a continuation of the company strategy focused on raising standards of drug production.
Michal Wieczorek, CEO of Davipharm, said: “The HP Zone in Davipharm answers the needs of Vietnam’s Ministry of Health, providing high-quality oncological drugs to Vietnamese patients. It will also increase the role of domestic drug manufacturers in optimizing the state budget, improve patient safety, and provide medicines to treat some of the most common diseases in Vietnam.
“Currently, eight out of ten people in Vietnam die from non-communicable diseases (NCDs), including cancers. This is also why Davipharm decided to be the first domestic drug manufacturer to become a partner of the Ministry of Health (MoH) in the prevention, early detection, and treatment of NCDs in Vietnam. We are proud to support MoH’s project ‘Vietnamese people giving priority to using Vietnamese drugs’”.
According to new regulations from Vietnam’s Ministry of Health, as well as guidelines from the World Health Organization (WHO), European Medicines Agency (EMA) and Pharmaceutical Inspection Co-operation Scheme (PIC/S), the production of certain products containing hazardous substances must be run at separate premises meeting specific criteria.
Davipharm’s portfolio includes 28 high potency (HP) drugs, among them oncology drugs for treatment of breast cancer, leukemia, pancreas, colorectal, stomach, cervix, prostate and lung cancer and glioblastoma.
The company has the capacity to produce batches from 15kg to 100kg with an annual output of five hundred million units of HP drugs. The total capacity of the factory is 1,800 million units a year.